Sarepta Shares Crash 25% After Third Patient Death Related Its Gene Therapy
Sarepta Therapeutics has confirmed a third patient death linked to its gene therapy programs, this time involving a 51-year-old man who died in June from acute liver failure after receiving the investigational therapy SRP-9004 for limb-girdle muscular dystrophy (LGMD).
The company confirmed the death to BioSpace and it was widely reported on Friday m…
Sarepta Shares Crash 25% After Third Patient Death Related Its Gene Therapy
July 18, 2025